SG11202002826VA - Immunomodulatory fusion proteins - Google Patents
Immunomodulatory fusion proteinsInfo
- Publication number
- SG11202002826VA SG11202002826VA SG11202002826VA SG11202002826VA SG11202002826VA SG 11202002826V A SG11202002826V A SG 11202002826VA SG 11202002826V A SG11202002826V A SG 11202002826VA SG 11202002826V A SG11202002826V A SG 11202002826VA SG 11202002826V A SG11202002826V A SG 11202002826VA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion proteins
- immunomodulatory fusion
- immunomodulatory
- proteins
- fusion
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564145P | 2017-09-27 | 2017-09-27 | |
| PCT/US2018/053197 WO2019067770A1 (en) | 2017-09-27 | 2018-09-27 | Immunomodulatory fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002826VA true SG11202002826VA (en) | 2020-04-29 |
Family
ID=65902489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002826VA SG11202002826VA (en) | 2017-09-27 | 2018-09-27 | Immunomodulatory fusion proteins |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11834492B2 (en) |
| EP (1) | EP3688037A4 (en) |
| JP (2) | JP2020536518A (en) |
| KR (1) | KR20200057070A (en) |
| CN (1) | CN111511769A (en) |
| AU (1) | AU2018338612A1 (en) |
| BR (1) | BR112020006115A2 (en) |
| CA (1) | CA3077223A1 (en) |
| EA (1) | EA202090838A1 (en) |
| IL (1) | IL273626A (en) |
| MX (1) | MX2020003672A (en) |
| SG (1) | SG11202002826VA (en) |
| WO (1) | WO2019067770A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019003445A (en) | 2016-09-27 | 2019-09-26 | Epicentrx Inc | Immunomodulatory fusion proteins. |
| WO2021147886A1 (en) * | 2020-01-21 | 2021-07-29 | 张晋宇 | Pharmaceutical composition and use thereof |
| CN113480662B (en) * | 2021-06-29 | 2022-07-22 | 北京双因生物科技有限公司 | Fusion protein containing CD40 antibody and IL-15, preparation method and application thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| AU3830895A (en) | 1994-10-07 | 1996-05-02 | Amgen Boulder Inc. | Dimeric il-4 inhibitors |
| AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| GB9626029D0 (en) | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
| US5998598A (en) | 1997-03-10 | 1999-12-07 | The United States Of America, As Represented By The Department Of Health And Human Services | Immunoadhesins and methods of production and use thereof |
| CN1257545A (en) | 1997-04-18 | 2000-06-21 | 拜奥根有限公司 | Type II TGF-beta receptor/immunoglobulin constant region fusion proteins |
| WO1999065948A1 (en) | 1998-06-16 | 1999-12-23 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| JP4944324B2 (en) | 1999-07-13 | 2012-05-30 | ボルダー バイオテクノロジー， インコーポレイテッド | Immunoglobulin fusion protein |
| EP1200479B1 (en) | 1999-08-09 | 2006-02-01 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| US7638604B2 (en) * | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| US20030125251A1 (en) | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
| WO2003066002A2 (en) * | 2002-02-08 | 2003-08-14 | University Of Medicine And Dentistry Of New Jersey | IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION |
| US20070184052A1 (en) | 2003-05-09 | 2007-08-09 | Lin Herbert Y | Soluble tgf-b type III receptor fusion proteins |
| JP4635255B2 (en) * | 2003-09-02 | 2011-02-23 | 独立行政法人産業技術総合研究所 | Antibody medicine |
| US20090155267A1 (en) * | 2005-02-09 | 2009-06-18 | Apollo Life Sciences Limited | Molecule and chimeric molecules thereof |
| WO2006084337A1 (en) * | 2005-02-14 | 2006-08-17 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| CN101146825A (en) * | 2005-02-14 | 2008-03-19 | 阿波罗生命科学有限公司 | A molecule and chimeric molecules thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20090175819A1 (en) * | 2005-11-15 | 2009-07-09 | Apollo Life Sciences Limited | Molecule and chimeric molecules thereof |
| EP2162472B1 (en) | 2007-05-30 | 2013-02-27 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
| JP2010529859A (en) | 2007-06-15 | 2010-09-02 | ジェンザイム、コーポレーション | Fusion protein containing two TGF-β binding domains of TGF-β type II receptor |
| WO2010031168A1 (en) | 2008-09-17 | 2010-03-25 | National Research Council Of Canada | HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY |
| EP2293667A4 (en) * | 2008-05-27 | 2012-07-18 | Kyowa Hakko Kirin Co Ltd | Interleukin 10 receptor (il-10r) antibodies and methods of use |
| JP2011526794A (en) | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | TGF-β antagonist multi-target binding molecule |
| SI3029144T1 (en) | 2009-03-02 | 2019-11-29 | Univ California | Tumor-selective adenovirus e1a and e1b mutants |
| EP3798237A1 (en) | 2010-03-05 | 2021-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| CN104334573A (en) | 2012-04-30 | 2015-02-04 | 比奥孔有限公司 | Targeted/immunomodulatory fusion proteins and methods for making same |
| RU2662991C2 (en) | 2013-03-12 | 2018-07-31 | Биокон Лтд. | Fusion immunomodulatory proteins and methods for making same |
| AU2014308751B2 (en) | 2013-08-22 | 2020-03-05 | Acceleron Pharma, Inc. | TGF-beta receptor type II variants and uses thereof |
| ES2778201T3 (en) | 2013-11-21 | 2020-08-10 | Brigham & Womens Hospital Inc | Compositions and methods for treating pulmonary hypertension |
| KR102363008B1 (en) | 2014-02-10 | 2022-02-16 | 메르크 파텐트 게엠베하 | TARGETED TGFβ INHIBITION |
| ES2824151T3 (en) | 2014-12-19 | 2021-05-11 | Alkermes Inc | Single-chain Fc fusion proteins |
| PT3288965T (en) * | 2015-04-29 | 2019-10-15 | Mediolanum Farm S P A | A soluble chimeric interleukin-10 receptor and therapeutic use thereof |
| CA2996996A1 (en) | 2015-08-31 | 2017-03-09 | National Research Council Of Canada | Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof |
| MX2019003445A (en) | 2016-09-27 | 2019-09-26 | Epicentrx Inc | Immunomodulatory fusion proteins. |
| US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
-
2018
- 2018-09-27 SG SG11202002826VA patent/SG11202002826VA/en unknown
- 2018-09-27 JP JP2020517588A patent/JP2020536518A/en not_active Withdrawn
- 2018-09-27 EP EP18862997.6A patent/EP3688037A4/en active Pending
- 2018-09-27 BR BR112020006115-8A patent/BR112020006115A2/en unknown
- 2018-09-27 WO PCT/US2018/053197 patent/WO2019067770A1/en active Application Filing
- 2018-09-27 US US16/651,079 patent/US11834492B2/en active Active
- 2018-09-27 EA EA202090838A patent/EA202090838A1/en unknown
- 2018-09-27 MX MX2020003672A patent/MX2020003672A/en unknown
- 2018-09-27 KR KR1020207011933A patent/KR20200057070A/en not_active Application Discontinuation
- 2018-09-27 AU AU2018338612A patent/AU2018338612A1/en active Pending
- 2018-09-27 CN CN201880075263.5A patent/CN111511769A/en active Pending
- 2018-09-27 CA CA3077223A patent/CA3077223A1/en active Pending
-
2020
- 2020-03-26 IL IL273626A patent/IL273626A/en unknown
-
2023
- 2023-05-16 JP JP2023081001A patent/JP2023096044A/en active Pending
- 2023-10-25 US US18/494,508 patent/US20240052016A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL273626A (en) | 2020-05-31 |
| AU2018338612A1 (en) | 2020-05-07 |
| EA202090838A1 (en) | 2020-08-28 |
| EP3688037A4 (en) | 2021-09-15 |
| WO2019067770A1 (en) | 2019-04-04 |
| MX2020003672A (en) | 2020-08-03 |
| CA3077223A1 (en) | 2019-04-04 |
| EP3688037A1 (en) | 2020-08-05 |
| JP2020536518A (en) | 2020-12-17 |
| US20200223901A1 (en) | 2020-07-16 |
| BR112020006115A2 (en) | 2020-11-17 |
| US20240052016A1 (en) | 2024-02-15 |
| JP2023096044A (en) | 2023-07-06 |
| KR20200057070A (en) | 2020-05-25 |
| CN111511769A (en) | 2020-08-07 |
| US11834492B2 (en) | 2023-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265657A (en) | Immunomodulatory fusion proteins | |
| HK1246317A1 (en) | Immunomodulatory fusion proteins and uses thereof | |
| HK1244019A1 (en) | Fusion proteins | |
| GB201509413D0 (en) | Fusion protein | |
| LT3180363T (en) | Sirp-alpha immunoglobulin fusion proteins | |
| HK1232136A1 (en) | P97-ids fusion proteins p97-ids | |
| GB201504691D0 (en) | Fusion protein | |
| ZA202003845B (en) | Fusion proteins | |
| GB201608197D0 (en) | Novel proteins | |
| SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
| IL273626A (en) | Immunomodulatory fusion proteins | |
| HK1257937A1 (en) | Fusion protein | |
| ZA202102533B (en) | Fusion protein | |
| GB2558968B (en) | G Proteins | |
| GB201602850D0 (en) | Fusion proteins | |
| EP3649159C0 (en) | Fusion protein | |
| GB201712792D0 (en) | Fusion protein | |
| EP3647426A4 (en) | Fusion protein | |
| HK1251456A1 (en) | Immunoglobulin fusion proteins and uses thereof | |
| GB201713537D0 (en) | Fusion Polypeptide | |
| GB201503789D0 (en) | Fusion polypeptide |